Skip to content
Head to head

Definium Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: DFTX · VRTX

Updated 3 minutes ago

1-year performance, rebased to 100

DFTX +149.9%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
DFTXVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price28.34515.02
Change today-3.87%-1.08%
1-year return+160.5%+22.0%
Market cap$3.88B$130.58B
52-week range10.53 – 49.70412.27 – 568.67
Valuation
P/E (TTM)-9.7133.14
P/E percentile, own 5-yr range9th99th
P/B4.016.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-2.0615.32
Net profit (TTM)$-282.01M$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin--33.1%
Net margin--30.7%
Free cash flow (TTM)$-191.36M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership93.1%96.8%
Insider activity (12mo)36 buy / 14 sell28 buy / 22 sell
Short interest (% of float)7.2%1.9%
Analyst consensus100% buy (14)95% buy / 5% hold (21)
Analyst price target$74 (+162%)$624 (+21%)
StockVane view
StockVane Quant RatingD (99)C (68)
Company
Employees1066,400
Founded20101989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.